At the basis of life, there are genes. It took over thirteen years to sequence the 2.85 billion nucleotides of the Human Genome. And while the mysteries of the sequence and its tens of thousands of genes were only beginning to emerge, a brand new way of looking at medical innovation was being defined.
1 Westmount Square, Suite 800
GeneChem Technologies Venture Fund L.P. was launched in early 1997 to take advantage of the increasing opportunities afforded by the emerging genomics sector. With committed capital of $100 million, we invested this first focused fund by targeting companies active in the field of genomics, which we defined as gene discovery, functional genomics, bio-informatics, proteomics and gene therapy. The companies in our portfolio developed tools, platforms or were involved in drug discovery.